Xencor's GAAP net income for 3 months of 2022 amounted to $23.594 million, compared to a loss of $2.487 million in the previous year. Revenue increased 2.5 times to $85.495 million from $33.965 million a year earlier.

Xencor's GAAP net income for 2021 was $82.631 million, compared to a loss of $69.333 million in the previous year. Revenue increased 2.2 times to $275.111 million from $122.694 million a year earlier.

Xencor has sold to Zenas BioPharma the exclusive rights to develop, manufacture and commercialize the investigational antibody obexelimab. The drug is a potential therapy for the treatment of COVID-19. Zenas will issue Xencor a warrant entitling it to acquire its additional shares, which will increase Xencor's stake in Zenas to 15%. Xencor will also receive...

Xencor' GAAP net income for 9M 2021 amounted to $9.57 mln, compared to a loss of $55.642 mln in the previous year. Revenue increased 49.8% to $121.096 million from $80.84 million a year earlier.